Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | FLT4 | P35916 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL7866 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL465143 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29371159 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28097850 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| CN-117479943-A | EGFR inhibitors and PERK activators in combination therapies and use thereof for treating cancer | 基因泰克公司 | 2024-01-30 | — | — | CN | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| EP-4747282-A1 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747283-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746922-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12636345-B2 | Methods of treating glioblastomas | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2022031749-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022028598-A1 | ATR INHIBITORS AND USES THEREOF | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2022-02-10 | — | — | WO | disclosed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11234971-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-02-01 | — | — | US | disclosed |
| CN-113968822-A | Gefitinib-resveratrol eutectic crystal | 鲁南制药集团股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956358-A | anti-TIGIT antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113952457-A | Application of termitimide or pharmaceutical composition containing termitimide in resisting coronavirus | 欣凯医药化工中间体（上海）有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636345-B2 | Methods of treating glioblastomas | EPHA2, EPHA3, EGFR | EGFR 3/4885KDR 84/4885BRAF 811/4885 |
| US-11234971-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | NR3C1, GRK4, GRK5 | EGFR 3111/4885KDR 3238/4885BRAF 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.